Effectiveness and tolerance of low to very low dose thalidomide in low-risk myelodysplastic syndromes

被引：11
作者：
Tamburini, J. [1 ]
Elie, C. [2 ]
Park, S. [1 ]
Beyne-Rauzy, O. [3 ]
Gardembas, M. [4 ]
Berthou, C. [5 ]
Mahe, B. [6 ]
Sanhes, L. [7 ]
Stamatoullas, A. [8 ]
Vey, N. [9 ]
Aouba, A.
Slama, B. [10 ]
Quesnel, B. [11 ]
Vekhoff, A. [13 ]
Sotto, J. J. [12 ]
Vassilief, D. [1 ]
Al-Nawakil, C. [1 ]
Fenaux, P. [14 ]
Dreyfus, F. [1 ]
Bouscary, D. [1 ]
机构：
[1] Hop Cochin, Dept Haematol, Paris, France
[2] Univ Paris 05, Dept Biostat, F-75270 Paris 06, France
[3] Hop Purpan, Dept Hematol Odile, Toulouse, France
[4] Ctr Hosp Angers, Dept Hematol Martine, Angers, France
[5] Hop Brest, Dept Hematol Christian, Brest, France
[6] Ctr Hosp Nantes, Dept Hematol, Nantes, France
[7] Ctr Hosp Perpignan, Dept Hematol, Perpignan, France
[8] Ctr Hosp Rouen, Dept Hematol Aspasia, Rouen, France
[9] Inst J Paoli I Calmettes, Dept Hematol, F-13009 Marseille, France
[10] Ctr Hosp Avignon, Dept Hematol, Avignon, France
[11] Ctr Hosp Lille, Dept Hematol, Lille, France
[12] Ctr Hosp Grenoble, Dept Hematol, Grenoble, France
[13] Hop Hotel Dieu, Dept Hematol, F-75181 Paris, France
[14] Hop Avicenne, Dept Hematol, Bobigny, France
来源：
LEUKEMIA RESEARCH | 2009年 / 33卷 / 04期
关键词：
INTERNATIONAL WORKING GROUP; RESPONSE CRITERIA; ANEMIA; PROPOSAL;
D O I：
10.1016/j.leukres.2008.06.005
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
[No abstract available]
引用
收藏
页码：547 / 550
页数：4
相关论文
共 50 条
  • [41] Erythropoietin plus granulocyte colony-stimulating factor is better than erythropoietin alone to treat anemia in low-risk myelodysplastic syndromes: results from a randomized single-centre study
    Enrico Balleari
    Edoardo Rossi
    Marino Clavio
    Angela Congiu
    Marco Gobbi
    Marco Grosso
    Vincenzo Secondo
    Mauro Spriano
    Silvana Timitilli
    Riccardo Ghio
    Annals of Hematology, 2006, 85 : 174 - 180
  • [42] Treatment of anemia in low risk myelodysplastic syndromes with granulocyte-macrophage colony-stimulating factor plus recombinant human erythropoietin
    Economopoulos, T
    Mellou, S
    Papageorgiou, E
    Pappa, V
    Kokkinou, V
    Stathopoulou, E
    Pappa, M
    Raptis, S
    LEUKEMIA, 1999, 13 (07) : 1009 - 1012
  • [43] Multicenter phase II trial of vitamin K2 monotherapy and vitamin K2 plus 1α-hydroxyvitamin D3 combination therapy for low-risk myelodysplastic syndromes
    Akiyama, Nobu
    Miyazawa, Keisuke
    Kanda, Yoshinobu
    Tohyama, Kaoru
    Omine, Mitsuhiro
    Mitani, Kinuko
    Ohyashiki, Kazuma
    LEUKEMIA RESEARCH, 2010, 34 (09) : 1151 - 1157
  • [44] Why group & save? Blood transfusion at low-risk elective caesarean section
    Stock, Owen
    Beckmann, Michael
    AUSTRALIAN & NEW ZEALAND JOURNAL OF OBSTETRICS & GYNAECOLOGY, 2014, 54 (03) : 279 - 282
  • [45] Identification of Very Low-Risk Subgroups of Patients with Primary Mediastinal Large B-Cell Lymphoma Treated with R-CHOP
    Vassilakopoulos, Theodoros P.
    Michail, Michail
    Papageorgiou, Sotirios
    Kourti, Georgia
    Angelopoulou, Maria K.
    Panitsas, Fotios
    Sachanas, Sotirios
    Kalpadakis, Christina
    Katodritou, Eirini
    Leonidopoulou, Theoni
    Kotsianidis, Ioannis
    Hatzimichael, Eleftheria
    Kotsopoulou, Maria
    Dimou, Maria
    Variamis, Eleni
    Boutsis, Dimitrios
    Terpos, Evangelos
    Dimopoulou, Maria N.
    Karakatsanis, Stamatios
    Michalis, Eurydiki
    Karianakis, George
    Tsirkinidis, Pantelis
    Vadikolia, Chryssa
    Poziopoulos, Christos
    Pigaditou, Anna
    Vrakidou, Effimia
    Economopoulos, Theophanis
    Kyriazopoulou, Lydia
    Siakantaris, Marina P.
    Kyrtsonis, Marie-Christine
    Symeonidis, Argyris
    Anargyrou, Konstantinos
    Papaioannou, Maria
    Hatjiharissi, Evdoxia
    Vervessou, Elissavet
    Tsirogianni, Maria
    Palassopoulou, Maria
    Gainaru, Gabriella
    Stefanoudaki, Ekaterini
    Zikos, Panayiotis
    Tsirigotis, Panayiotis
    Tsourouflis, Gerasimos
    Assimakopoulou, Theodora
    Konstantinidou, Pavlina
    Papadaki, Helen A.
    Megalakaki, Katerina
    Dimopoulos, Meletios-Athanasios
    Pappa, Vassiliki
    Karmiris, Themis
    Roussou, Paraskevi
    ONCOLOGIST, 2021, 26 (07) : 597 - 609
  • [46] Weekly standard doses of rh-EPO are highly effective for the treatment of anemic patients with low-intermediate 1 risk myelodysplastic syndromes
    Balleari, Enrico
    Clavio, Marino
    Arboscello, Eleonora
    Bellodi, Andrea
    Bruzzone, Andrea
    Del Corso, Lisette
    Lucchetti, Maria Vita
    Miglino, Maurizio
    Passalia, Caterina
    Pierri, Ivana
    Ponassi, Irene
    Oneto, Caterina
    Racchi, Omar
    Scudeletti, Marco
    Vignolo, Luana
    Zoppoli, Gabriele
    Gobbi, Marco
    Ghio, Riccardo
    LEUKEMIA RESEARCH, 2011, 35 (11) : 1472 - 1476
  • [47] Risk Factors of Transfusion in Anemia of Very Low Birth Weight Infants
    Jeon, Ga Won
    Sin, Jong Beom
    YONSEI MEDICAL JOURNAL, 2013, 54 (02) : 366 - 373
  • [48] Activin Receptor II Ligand Traps: New Treatment Paradigm for Low-Risk MDS
    Komrokji, Rami S.
    CURRENT HEMATOLOGIC MALIGNANCY REPORTS, 2019, 14 (04) : 346 - 351
  • [49] Reference intervals for hemoglobin and hematocrit in a low-risk pregnancy cohort: implications of racial differences
    Chiossi, Giuseppe
    Palomba, Stefano
    Costantine, Maged M.
    Falbo, Angela I.
    Harirah, Hassan M.
    Saade, George R.
    La Sala, Giovanni B.
    JOURNAL OF MATERNAL-FETAL & NEONATAL MEDICINE, 2019, 32 (17) : 2897 - 2904
  • [50] Amifostine has the potential to induce haematologic responses and decelerate disease progression in individual patients with low- and intermediate-1-risk myelodysplastic syndromes
    Schanz, Julie
    Jung, Heike
    Woermann, Bernhard
    Gassmann, Winfried
    Petersen, Thomas
    Hinke, Axel
    Haase, Detlef
    LEUKEMIA RESEARCH, 2009, 33 (09) : 1183 - 1188
12345